Get started

Financials · CRDF

Cardiff Oncology Inc. (CRDF) financials

For the twelve months ended Jun 30, 2026, Cardiff Oncology Inc. reported $508.0K of revenue and -$40.05M of net income.

Revenue, TTM
$508.0K
Revenue growth, YoY
-7.0%
Net income, TTM
-$40.05M
Net margin
-7884.1%
EPS, diluted, TTM
-$0.60
Cash
$9.20M
P/S
121.79
Market cap
$61.9M
Annual revenue$593.0K
FY2016FY2025
Annual net income-$45.85M
FY2016FY2025
Annual free cash flow-$37.97M
FY2016FY2025

CRDF revenue and earnings growth

CRDF revenueQ2 2026$104.0K

Quarter YoY
-14.0%
QoQ
+153.7%
FY YoY
-13.2%
5Y CAGR
+10.1%
10Y CAGR
+6.6%

CRDF revenue was $104.0K in fiscal Q2 2026 (ended Jun 30, 2026), down 14.0% from a year earlier and up 153.7% from the prior quarter. For the full fiscal 2025 it was $593.0K, down 13.2% from fiscal 2024. Compound annual growth was +10.1% over 5 years and +6.6% over 10 years. It rose in 6 of the last 10 fiscal years.

CRDF net incomeQ2 2026-$9.23M

CRDF net income was -$9.23M in fiscal Q2 2026 (ended Jun 30, 2026), compared with -$13.94M a year earlier. For the full fiscal 2025 it was -$45.85M, compared with -$45.43M in fiscal 2024.

CRDF EPSQ2 2026-$0.14

CRDF diluted EPS was -$0.14 in fiscal Q2 2026 (ended Jun 30, 2026), compared with -$0.21 a year earlier. For the full fiscal 2025 it was -$0.69.

CRDF free cash flowQ4 2025-$5.97M

CRDF free cash flow was -$5.97M in fiscal Q4 2025 (ended Dec 31, 2025), compared with -$10.27M a year earlier. For the full fiscal 2025 it was -$37.97M, compared with -$37.77M in fiscal 2024.

Export CSV

Income statement

Income statement
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
FY2018
Dec 31, 2018
FY2017
Dec 31, 2017
FY2016
Dec 31, 2016
Revenue$593.0K$683.0K$488.0K$386.0K$359.0K$366.0K$244.6K$378.3K$505.4K$381.1K
Cost of revenue------$0$597.5K$1.81M$1.73M
Gross profit------$244.6K-$219.1K-$1.31M-$1.35M
Research and development$35.33M$36.85M$32.86M$27.11M$17.38M$11.23M$11.16M$8.16M$7.88M$15.01M
Selling, general and admin$14.22M$12.48M$13.04M$13.18M$11.84M$8.22M$5.76M$8.01M$14.23M$11.48M
Operating income-$48.96M-$48.65M-$45.41M-$39.90M-$28.86M-$19.09M-$16.68M-$17.05M-$25.60M-$40.15M
Interest expense----$0$2.0K$0$25.4K$1.03M$1.67M
Pre-tax income-$45.85M-$45.43M--------
Income tax$0$0$0$0$0$0$0$0$0$0
Net income-$45.85M-$45.43M-$41.44M-$38.70M-$28.29M-$19.31M-$16.41M-$16.46M-$24.91M-$39.20M
EPS, basic-$0.69-$0.95-$0.93-$0.89-$0.73-$1.08-$2.80-$8.26-$310.56-$93.60
EPS, diluted-$0.69-$0.95-$0.93-$0.89-$0.73-$1.08-$2.80-$8.26-$310.56-$98.64
Diluted shares66.8M47.6M44.7M43.6M39.0M20.9M6.0M2.3M80,278.667420,573.097

Balance sheet

Balance sheet
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
FY2018
Dec 31, 2018
FY2017
Dec 31, 2017
FY2016
Dec 31, 2016
Cash and equivalents$17.47M$51.47M$21.66M$16.35M$11.94M$130.98M$10.20M$11.45M$8.23M$13.92M
Short-term investments$40.83M$40.28M$53.17M$88.92M$128.88M$0--$0$23.98M
Receivables$182.0K$773.0K$288.0K$771.0K$535.0K$320.0K$203.5K$167.8K$77.1K$100.5K
Current assets$60.13M$95.05M$77.41M$111.28M$146.13M$133.36M$11.35M$12.77M$9.47M$38.95M
Total assets$61.88M$97.19M$81.64M$116.19M$149.54M$134.73M$13.09M$14.17M$12.28M$43.95M
Current liabilities$16.39M$13.43M$10.44M$7.81M$6.56M$6.12M$4.78M$2.92M$3.95M$7.80M
Long-term debt--------$0$14.18M
Total debt--------$0$14.18M
Total liabilities$16.50M$14.24M$11.90M$9.85M$9.13M$6.57M$5.78M$4.09M$5.78M$24.18M
Shareholders' equity$45.39M$82.95M$69.74M$106.34M$140.42M$128.16M$7.31M$10.08M$6.51M$19.77M

Cash flow

Cash flow
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
FY2018
Dec 31, 2018
FY2017
Dec 31, 2017
FY2016
Dec 31, 2016
Operating cash flow-$37.92M-$37.69M-$30.89M-$33.82M-$23.04M-$16.32M-$13.27M-$13.20M-$23.28M-$31.04M
Capital expenditures$44.0K$80.0K$582.0K$1.01M$205.0K$211.0K$67.6K$5.1K$101.1K$823.5K
Free cash flow-$37.97M-$37.77M-$31.47M-$34.83M-$23.25M-$16.53M-$13.34M-$13.20M-$23.38M-$31.86M
Investing cash flow$1.34M$13.73M$36.20M$38.15M-$131.45M-$211.0K-$67.6K$22.8K$23.96M-$24.83M
Financing cash flow$2.58M$53.78M$0$75.0K$35.45M$137.31M$12.08M$16.40M-$6.38M$2.30M
Stock-based compensation$5.69M$4.76M$4.51M$4.26M$3.23M$1.76M$884.9K$2.17M$4.01M$7.50M
Depreciation and amortization$364.0K$404.0K$398.0K$236.0K$451.0K$466.0K$494.2K$859.5K$1.25M$1.07M

Key ratios

Key ratios
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
FY2018
Dec 31, 2018
FY2017
Dec 31, 2017
FY2016
Dec 31, 2016
Revenue growth, YoY-13.2%40.0%26.4%7.5%-1.9%49.6%-35.3%-25.1%32.6%21.8%
Gross margin------100.0%-57.9%-258.4%-354.1%
Operating margin-8256.3%-7123.1%-9305.7%-10337.3%-8037.6%-5214.8%-6817.8%-4507.6%-5064.4%-10534.9%
Net margin-7732.0%-6651.7%-8492.0%-10026.9%-7880.5%-5275.1%-6709.7%-4351.1%-4928.1%-10287.7%
Free cash flow margin-6402.5%-5530.5%-6448.6%-9022.3%-6474.9%-4515.3%-5451.1%-3490.2%-4626.4%-8361.5%
Return on equity-101.0%-54.8%-59.4%-36.4%-20.1%-15.1%-224.5%-163.2%-382.8%-198.3%
Return on assets-74.1%-46.7%-50.8%-33.3%-18.9%-14.3%-125.4%-116.1%-202.7%-89.2%
Current ratio3.677.087.4114.2522.2821.792.374.372.405.00
Debt to equity--------0.000.72

Source: XBRL data Cardiff Oncology Inc. files with the SEC, latest filing dated Aug 11, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.

* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.

Per-share figures and share counts are restated for stock splits the filings show: 1-for-12, first reported Aug 3, 2018; 1-for-6, first reported Aug 8, 2019.

EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.

CRDF peers

CompanyRevenueGrowthNet incomeNet marginMarket cap
CRDF$508.0K-7.0%-$40.05M-7884.1%$61.9M
AMGN$38.90B+8.2%$9.39B24.1%$251.65B
GILD$30.99B+6.5%-$3.86B-12.5%$210.01B
MRNA$2.52B+13.1%-$2.79B-110.5%$107.39B
ARGX$4.25B+88.6%$1.29B30.4%$59.72B
RVMD$0--$1.13B-$43.29B
BIIB$10.30B+2.3%$347.50M3.4%$37.67B
BNTX€2.87B+4.3%-€1.14B-39.6%$21.98B
EXEL$2.50B+9.1%$885.14M35.5%$17.51B

CRDF FAQ

7 questions
  • What is CRDF revenue?
    Cardiff Oncology Inc. (CRDF) reported $508.0K of revenue for the twelve months ended Jun 30, 2026. That is down 7.0% from the year before. Revenue for fiscal 2025 was $593.0K.
  • Is CRDF profitable?
    No. Cardiff Oncology Inc. reported a net loss of $40.05M for the twelve months ended Jun 30, 2026.
  • How much cash and debt does CRDF have?
    Cardiff Oncology Inc. reported $9.20M in cash and cash equivalents on its most recent balance sheet in SEC filings.
  • How fast is CRDF revenue growing?
    Cardiff Oncology Inc.'s revenue changed -13.2% in fiscal 2025, to $593.0K. Its compound annual growth rate was +10.1% over 5 years and +6.6% over 10 years.
  • What is CRDF earnings per share?
    Diluted earnings per share were -$0.60 for the twelve months ended Jun 30, 2026, from SEC filings, restated for any stock split those filings show.
  • When did CRDF last report financial results?
    The latest statements here come from Cardiff Oncology Inc.'s 10-Q filed on Aug 11, 2026, covering the period ended Jun 30, 2026.
  • Where does this CRDF financial data come from?
    Quantisnow builds these statements from the structured XBRL data Cardiff Oncology Inc. files with the SEC. It is provided for information only and is not investment advice.